drugset / Trial / NCT01751399
A Single Dose Study of LY2605541 in Participants With Liver Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to help answer the following research questions: * To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function * To assess the safety of LY2605541 and any side effects that might be associated with it
Timeline
- Start
- 2012-12
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Peglispro | Protein / enzyme biologic | 0.075 mg/kg | Subcutaneous |